Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aloperine is a **quinolizidine alkaloid** primarily extracted from the roots of the plant *Sophora alopecuroides*. It is a natural product with documented biological activities including anti-inflammatory, antiviral, antitumor (anticancer), and immunomodulatory effects. Mechanistically, aloperine has been shown to inhibit various targets and pathways, such as PI3K/Akt, NF-κB, and Bcl-2 family proteins, depending on the disease model (notably in inflammation and cancers). It is not approved as a pharmaceutical but is researched as a bioactive lead compound in drug discovery for multiple disease indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aloperine.